The EU is currently reviewing its Pharmaceutical Legislation, and the latest IQVIA white paper “Assessing the biosimilar void” sheds light on the growing biological medicines market and the opportunity to improve equitable access with biosimilar medicines competition.
The huge biosimilar void to 2032: The report warns that €15 billion worth of biological medicines losing exclusivity has no visible biosimilar competition. This represents nearly 25% of the total opportunity.
Correcting course on access to biologics: Facing a widening of access disparities, the white paper identifies key regulatory and market policy reforms that could stimulate investment in biosimilar development and smarter use of biosimilar medicines.
Faster Access: It is critical to stimulate biosimilar development by enhancing regulatory efficiency at EU level, by way of regulatory streamlining in line with science and experience and, through a more dynamic approach to removing access barriers (e.g. reimbursement) at biosimilar entry.
The IQVIA report provides a comprehensive analysis of what needs to be done to support biosimilar medicines development and competition up to 2032 by the European Institutions, the EMA, the HMA, and EU Member States.
Commenting on the launch of the IQVIA report, Julie Marechal-Jamil, Director Biosimilar Policy & Science at Medicines for Europe said: “So far, biosimilar medicines have delivered huge access benefits for patients and savings for healthcare budgets. Biosimilar medicines play an undeniable role in the future of competition and access pillars in the pharmaceutical legislative process. We need to jump start the multistakeholder policy process ensuring more biosimilar medicines development and access, as patient demand for biological medicines increases. This report identifies many policy shortcomings that must be addressed now to deliver access to medicines in the future.”
👉 20231026-Press-release-Assessing-the-biosimilar-void.pdf (medicinesforeurope.com)
